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SARA series of imidazopyrid azines which are potent inhibitors of Plasmodium falciparum calcium-dependent
protein kinase 1 (PfCDPK1) was identiﬁed from a high-through put screen against the isolated enzyme.
Subsequent exploration of the SAR and optimisation has yielded leading members which show promising 
in vitro anti-parasite activity along with good in vitro ADME and selectivity against human kinases. Initial 
in vivo testing has revealed good oral bioavailability in a mouse PK study and modest in vivo efﬁcacy in a
Plasmodium berghei mouse model of malaria.
 2013 Elsevier Ltd. Open access under CC BY license.Malaria is one of the most prevalent infectious diseases of the 
developing world. In excess of 3 billion people are at risk, and it 
currently leads to the deaths of almost 1 million people each year,
with the majority of these occurring in sub-Saharan Africa among 
children under 5 years of age.1 Resistance to existing anti-malarial 
drugs is widespread 2 and therefore new therapeutic approach es 
are urgently needed. Calcium-depend ent protein kinases (CDPKs)
are directly regulated by Ca 2+ and are found in plants and organ- 
isms in the alveolate lineage,3 but are absent in humans. They 
are present in Apicomplexa n parasites including Plasmodium falci- 
parum, the causative agent of the most severe form of malaria.
CDPKs in Plasmodiu m are present as a multigene family containing 
at least ﬁve members,4 and different CDPKs are proposed to be 
functional at different stages of the parasite life cycle. P. falciparum 
calcium-dep endent protein kinase 1 (PfCDPK1), ﬁrst identiﬁed by 
Zhao et al.,5 is expresse d in the asexual blood stages of the parasite 
responsible for disease pathology. It has been shown to be encoded 
by an essential gene 6 and it is implicated in parasite motility and 
host cell invasion, where it is able to phospho rylate components 
of the molecular motor that drive parasite invasion of red blood 
cells.7 If this invasion process can be prevented the parasite lifecycle would be broken, leading the parasites to die and the 
infection to be cleared. PfCDPK1 therefore represents a novel target 
for the potential treatment of malaria and offers promise for 
achieving selectivity over the kinases of the human host. More re- 
cently its role in translationa l regulation of motor complex tran- 
scripts has been reported 8 but hitherto few inhibitors of PfCDPK1
have been described in the literature.9
A high throughput screen of our compound collection against 
the isolated recombinant PfCDPK1 enzyme was performed 10 and
a series containing a 3,6-disubstituted imidazopyri dazine core 
template was identiﬁed as the primary series of interest (Fig. 1).
Early examples with R1 as a 2- or 3-aminoe thylpyridyl group and 
R2 as a phenyl ring carrying an appended amide, cyano or ﬂuoro
group all showed sub-100 nanomolar IC 50 values against the en- 
zyme (Table 1). Initial screening of these compound s against the 
P. falciparum parasite in vitro showed strong inhibition of parasite 
growth in a number of cases. However, despite the promising po- 
tency of these early compounds , they typically showed high log D
values and low stability in microsom es. Furthermor e, they exhib- 
ited poor selectivity for PfCDPK1 over a panel of human kinases,
and their anti-parasit e effect may be driven by signiﬁcant
off-target activity. Related imidazopyri dazines have been de- 
scribed in the literature as effective inhibitors of other kinases such 
as human PIM kinase,11 IKKb12 and malarial PfPK7.13
Table 1
Examples from hit series 
Compound R1 R2 PfCDPK1 IC 50 (lM) P. falciparum growth inhibition a (%)
1
N N
H
O NH2
0.059 99
2
N N
H
O NH2
0.061 99
3 N N
H N
H
O
0.066 35 
4
N N
H
CN
0.071 98 
5 N N
H F
0.080 6
a At 1 lM inhibitor concentration.
N N
N
R1
R2
Figure 1. 3,6-Imidazopyridazine hit core template.
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potency alongside the selectivity, ADME and physical propertie s of 
the series. In order to assist compound design, a homology model 
of PfCDPK1 was built based on the published crystal structure of 
TgCDPK114 and docking studies using Glide (Schrödinger Inc.) sug- 
gested that the imidazopyrida zine core could form a key H-bond 
interaction between the nitrogen at the 1-positio n and the back- 
bone N-H of Tyr-148 at the kinase hinge region (Fig. 2).
The aminoethyl pyridine group at R1 could form an interactio n
with the Lys-85 but was also directed towards the Glu-152 residue 
at the entrance to the pocket, leading out towards solvent. The R2
portion was proposed to occupy a pocket where the model sug- 
gested there was sufﬁcient space to append larger groups onto the 
phenyl ring. This offered a potential opportunity to gain improved 
potency and selectivity in comparis on to compounds such as 1
and 2.
Synthesis of a range of analogues with variation of the groups at 
both R1 and R2 was undertaken in order to build the SAR, and 
examples given in Table 2 illustrate the results from assays against 
both the PfCDPK1 enzyme and P. falciparum parasite.15 It was rap- 
idly found that the pyridyl group at the R1 position of the molecule 
was less important in contributing to the binding afﬁnity than the 
core and R2 groups, so this R1 could be replaced with a more basic 
amine group with the aim of lowering the log D and improving the 
ADME and physical properties of the compounds . Exploration of a
range of different basic amine side chains at R1 revealed that N-
methyl piperidine and 1,4-diami nocyclohexane in particular gave 
good enzyme afﬁnity. At the R2 position, N-linked phenyl amides 
and carbamates showed good enzyme afﬁnity and sub-microm olar 
EC50 values against the P. falciparum parasite (Table 2, examples 6–
8). C-linked phenyl amides also showed good enzyme afﬁnity: arange of different alkyl groups were investigated and the isopentyl 
group was found to be optimal for enzyme afﬁnity (examples 9 and
10) with sub-micromola r anti-parasit e EC 50. Compounds were pre- 
pared following the synthetic route shown in Scheme 1: installa- 
tion of the basic amine side chain was achieved by nucleophilic 
substitut ion at the 6-chloro substitue nt of 11 to afford the interme- 
diates 12 and 14. The 3-position N-linked amides or carbamate 6–8
were accessed by Suzuki coupling either directly or through the 
intermedi ate aniline 15 with subsequent functionalis ation. The 4- 
position C-linked amides were accessed by Suzuki coupling fol- 
lowed by hydrolysis to give the carboxylic acids 13 and 16 then
amide coupling with isopentyl amine.
In order to try to further improve the physical propertie s of the 
compounds , decrease the log D and improve anti-parasit e potency,
replacemen t of the phenyl ring attached to the imidazop yridazine 
core with a heteroary l ring was investigated .
The replacemen t of the phenyl ring by pyridyl and directly 
linking the alkylamine to the pyridyl ring resulted in a compound 
with good enzyme afﬁnity and sub-500 nanomolar cell potency 
(Table 3, example 17), which also displayed a good in vitro ADME 
proﬁle (see Table 6). A range of alternative alkyl groups was ex- 
plored and while changes could be accommod ated (e.g., 18 and
19), none were superior to the isopentyl group for potency.
The introduction of polarity led to a small loss in potency (20)
and the alternativ e pyridine isomer carrying the isopentylam ine 
substitue nt (21) displayed a sevenfold loss in potency against 
the enzyme in comparison to 17. The compounds were obtained 
through the synthetic route shown in Scheme 2: Suzuki cou- 
pling gave the chloropyridine intermediates 22 and 23 and
the alkylamines were subsequent ly introduced by nucleophilic 
displacemen t.
Figure 2. Proposed binding orientation from docking of compound 1 in homology model of PfCDPK1.
Table 2
SAR with basic amine groups at R1 and substituted phenyl groups at R2
Compound R1 R2 PfCDPK1 IC 50 (lM) P. falciparum EC50 (lM)
6 N
H
NH2
N
H
O
0.011 0.32 
7 N
H
N
N
H
O
0.022 0.56 
8 N
H
N
N
H
O
OMe 0.018 0.75 
9 NH
NH2
O
N
H
0.016 0.46 
10
N
H
N
O
N
H
0.023 0.78 
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explored (Table 4). This showed that reducing the size of the ring to 
the pyrrolidine was well tolerated (24), however the azetidine (25)
lost signiﬁcant potency against both the enzyme and parasite, and 
this was also observed for the N-methyl piperazine (26). As pre- 
dicted by the homology model the presence of the NH was not 
found to be essential: although the 4-dimethyla minopiperidin e
(27) was less potent than compound 17, its desmeth yl analogue 
(28) showed good potency against both the enzyme and parasite.
Similarly, the compound 17 analogue without the N-methyl group 
(29) was well accommodated , with no loss in enzyme binding 
afﬁnity and slightly improved anti-paras ite activity.Returnin g to the R2 position, further changes in the heteroary l
ring and the appende d groups were investigated (Table 5). The nitro- 
gen linker atom between the heteroaryl ring and the alkyl chain was 
replaced with an oxygen atom, by performing a nucleophilic substi- 
tution with isopentyl alcohol deprotonated with sodium hydride in 
place of the amine. However , the product (30) showed a signiﬁcant
loss in potency, indicating the importance of this N–H donor.
Replacemen t of the pyridine ring with pyrimidine was investiga ted,
and this revealed that compounds containing the pyrimidine at- 
tached to the core through the 5-position (31 and 32) showed good 
inhibitory activity whereas attachment at the 4-position (33) re- 
sulted in a signiﬁcant loss of potency against the enzyme.
Table 3
SAR with heteroaryl R2 (nt = not tested)
N N
N
N
H
N
R2
Compound R2 PfCDPK1 IC 50 (lM) P. falciparum EC50 (lM)
17 N
N
H
0.013 0.40 
18 N
N
H
0.014 0.43 
19 N
N
H
0.036 0.45 
20 N
N
H
OMe
0.025 0.67 
21
N
N
H
0.088 nt 
N N
N
Cl
Br
N N
N
N
H Br
NH
O O
N N
N
N
H Br
N
N N
N
N
H
NH
CO2H
OO
N N
N
N
H
N
CO2H
N N
N
N
H
N
NH2
(11)
(12)
(13)
(6)
(9)
(14)(16)
(7) or (8)
(10)
(15)
(a) (b), (c)
(g)(h), (c) (d), (e)
(f)
(i) or (j)
(f) (d), (e)
Scheme 1. Reagents and conditions: (a) 1,4-cyclohexanediamine, dioxane/NMP, microwave, 180 C then di- tert-butyldicarbonate, DMAP, CH 3CN, 50 C; (b) 3- 
acetamidophenylboronic acid pinacol ester, Pd(dppf)Cl2, aq Na 2CO3, dioxane, reﬂux; (c) 4 M HCl/dioxane; (d) 4-ethoxycarbonylphenylboronic acid, Pd(dppf)Cl2, aq Na 2CO3,
dioxane, reﬂux; (e) LiOH, THF/MeOH/H 2O; (f) isopentylamine, TBTU, DIPEA, and DMF; (g) 1-methyl-4-aminopiperidine, NMP, microwave, 180 C; (h) 3- N-tert-
butoxycarbonylaminophenylboronic acid, Pd(dppf)Cl2, aq Na 2CO3, dioxane, reﬂux; (i) cyclopropanecarbonyl chloride, DIPEA, and CH 2Cl2; (j) methyl chloroformate, DIPEA,
CH 2Cl2.
T. M. Chapman et al. / Bioorg. Med. Chem. Lett. 23 (2013) 3064–3069 3067The synthetic routes used to access these analogues are detailed 
in Scheme 3: installation of the S-methyl pyrimidine through Suzu- 
ki coupling on the BOC-protec ted compounds 34 and 12 gave the 
intermediates 35–37. These were functionalised through oxidation 
of the S-methyl group using mCPBA and subsequent introduction 
of the alkylamine by nucleophilic substitution . The sequence was 
completed by removal of the BOC protecting group and then in 
the case of the piperidine by the introduction of the N-methyl
group through reductive amination.
Overall, the introduction of a basic side chain at the R1 position
and a heteroary l ring with an appended aminoalkyl group at R2 led
to improved potency, physical properties and in vitro ADME char- 
acteristics compare d with the initial hits. These compounds dis- 
played lower log D and higher stability in both mouse and human microsom es alongside signiﬁcant improvem ents in kinase selectiv- 
ity against a human kinase panel.
Compounds possessing the best proﬁles with respect to po- 
tency, in vitro ADME and selectivity were advanced to testing for 
in vivo efﬁcacy in a P. berghei mouse model of malaria. In advance 
of in vivo testing, it was shown that the inhibitors retained potency 
against the isolated P. berghei CDPK1 enzyme.16 Compounds were 
dosed with an oral, once daily 50 mg/kg regime over 4 days in 
the standard Peters test, and their in vitro ADME and in vivo efﬁ-
cacy data is shown in Table 6. The best efﬁcacy was displayed by 
compound 17, with a 46% reduction in the level of parasitaem ia 
relative to vehicle. This offers promise at this stage considering 
the relatively modest cellular potency of these compounds and 
17 represents an interesting early lead. PK proﬁling of compound 
Table 6
In vitro ADME and in vivo efﬁcacy data for selected compounds 
Compound
17 24 27 28 
PfCDPK1 IC 50 (lM) 0.013 0.023 0.044 0.013 
P. falciparum EC50 (lM) 0.40 0.17 0.57 0.14 
MLM a (% rem) 63 74 84 90 
HLM a (% rem) 85 63 80 90 
m logD 3.4 3.5 3.2 2.5 
PAMPA Papp (nm s1) 81 114 137 55
Reduction in parasitaemia in vivo b (%) 46 30 7 11
a % Remaining at 30 min.
b 4-Day Peters test in P. berghei mouse model, with oral dosing once daily at 
50 mg/kg; compounds were dissolved or suspended in 70/30 Tween-80/ethanol 
and diluted 10-fold with water before dosing.
Table 4
SAR with alternative basic amine groups 
N N
N
N
N
H
R1
Compound R1 PfCDPK1 IC 50 (lM) P. falciparum EC50 (lM)
24 N
H
N
0.023 0.17 
25 N
H
N
0.089 0.93 
26
N
N 0.175 2.40 
27
N
N 0.044 0.57 
28
N
NH2
0.013 0.14 
29 N
H
NH
0.015 0.24 
N N
N
N
H
N
N
Cl
N N
N
N
H
N
N
Cl
N N
N
N
H
N
N
N
H
N N
N
N
H
N
N
N
H R
O
(b)
(14)
(a)
(c)
(b)
(22)
(23)
(21)
R= i-pentyl (17)
n-butyl  (18)
(19)
(20)
Scheme 2. Reagents and conditions: (a) 2-chloro-5-pyridine boronic acid,
Pd(dppf)Cl2, aq Cs 2CO3, THF, reﬂux; (b) RNH 2, NMP, microwave, 190 C; (c) 2- 
chloro-4-pyridine boronic acid, Pd(dppf)Cl2, aq Cs 2CO3, THF, reﬂux.
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availability in mouse (Fig. 4), although it displayed moderate to 
high clearance.
Compounds 17, 24 and 28 exhibited good selectivity proﬁles
when screened against a panel of human kinases at 1 lM inhibitor 
concentratio n (Fig. 3).17 Pleasingly, screening against the isolated 
CDPK1 enzyme of the related malarial parasite Plasmodium vivax 
revealed that these compounds were highly potent against this 
species,16 which is also an important human pathogen causing 
considerable morbidit y.Table 5
SAR proﬁles with alter native R2 heteroaryl groups or heteroatom linkers (nt = not tested)
N N
N
R1
R2
Compound R1 R2 PfCDPK1 IC 50 (lM) P. falciparum EC50 (lM)
30 N
H
NH2
N
O
0.170 0.54 
31
N
H
N
N
N
N
H
0.014 0.47 
32 N
H
NH2
N
N
N
H
0.016 0.17 
33 N
H
N
N
N
N
H
0.424 nt 
NN
SN
N
S
N N
N
N
H
N
N
N
N
H
N
N
N
H
N N
N
Br
N
H
N
O
O
N N
N
N
H
NO
O
N N
N
N
H
NH2
N
N
N
H
N N
N
N
H
N
N
S
NH
OO
R2 = R2 = 
(c), (d), (e), (f)
or or
(a) or (b)
(a)
(34)
(12)
(37) (32)
(35) (36)
(31)
(33)
(c), (d), (e)
R2 R2
Scheme 3. Reagents and conditions: (a) 2-(methylthio)pyrimidine-5-boronic acid pinacol ester, Pd(dppf)Cl2, aq Cs 2CO3, dioxane, reﬂux; (b) 2-(methylthio)pyrimidine-4-
boronic acid pinacol ester, Pd(dppf)Cl2, aq Cs 2CO3, dioxane, reﬂux; (c) m-chloroperoxybenzoic acid, CH 2Cl2; (d) isopentylamine, dioxane, 65 C; (e) 4 M HCl/dioxane; (f)
formaldehyde, AcOH, Na(OAc)3BH, THF.
Compound
17
24
28
Kinase
Figure 3. Kinase selectivity data on selected compounds screened at 1 lM inhibitor 
concentration against a 73-member human kinase panel; green: <50% inhibition;
amber: 50–80% inhibition; red: >80% inhibition. Kinases hit by compound 17 are:
MKK1, RSK1, PKD1, CHK2, Aurora B, NUAK1, GCK, MLK1, Src, Lck, YES1, and VEGFR;
compound 24: RSK1 and HER4; compound 28: RSK1, CAMK1, PHK, NUAK1, and 
HER4.
i.v. t1/2  2.0 h 
Clint  2984 mL/h/kg 
Oral %F  84% 
ppb  86% 
Figure 4. Mouse pharmacokinetic and plasma-protein binding data for compound 
17.
T. M. Chapman et al. / Bioorg. Med. Chem. Lett. 23 (2013) 3064–3069 3069In summary, a series of imidazopyrida zines which are potent 
inhibitors of PfCDPK1 has been identiﬁed. Leading compounds 
have shown promising in vitro anti-parasite activity, in vitro ADME 
and kinase selectivity proﬁles and in vivo pharmac okinetics in 
mouse, with modest in vivo efﬁcacy in a P. berghei mouse model 
of malaria. Improving the in vitro anti-parasit e activity, in vivo efﬁ-
cacy and PK proﬁle of this series is the subject of further work and 
will be described in a future publication.
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